Postmastectomy Radiation Therapy in Patients With Minimally Involved Lymph Nodes: A Review of the Current Data and Future Directions

다국어 초록 (Multilingual Abstract)

Radiation therapy for patients with pN1mi or pN1 disease breast cancer undergoing mastectomy has been debated for a long time. Even in low metastatic burden in sentinel node biopsy, occult non-sentinel axillary nodal involvement can exist. Radiotherapy can sterilize axillary metastatic burden and seems to contribute a very low local recurrence rate in mastectomy patients with minimally involved lymph nodes. However, it should be considered that systemic therapy is evolving and the local recurrence difference between radiotherapy and no radiotherapy is relatively small. Regarding postmastectomy radiotherapy in patients pN1mi or pN1 cancer, published prospective clinical trial results should be considered; however, there are no such relevant results of clinical trials yet. Consideration of postmastectomy radiation therapy in pN1mi or pN1 patients should be based on identifying the high-risk group in terms of recurrence, stage, or tumor biology. When radiotherapy is determined, radiation oncologists should attempt individualized treatment approaches, such as irradiation field, and consider specific settings, such as neoadjuvant therapy. In this review, the role of radiotherapy in mastectomy patients with minimally involved lymph nodes and the relevant considerations are discussed.

참고문헌 (Reference)

1 Montero Á, "When can we avoid postmastectomy radiation following primary systemic therapy?" 21 : 95-, 2019

2 Kim SW, "What is high-risk breast cancer with pathologically negative lymph nodes for regional recurrence?" 111 : 992-998, 2021

3 Rusthoven CG, "The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis" 27 : 818-827, 2016

4 Ma JC, "The effect of postmastectomy radiotherapy on breast cancer patients after neoadjuvant chemotherapy by molecular subtype" 28 : 5084-5095, 2021

5 Patel M, "The effect of post mastectomy radiation therapy on survival in breast cancer patients with N1mic disease" 51 : 50-56, 2020

6 Straver ME, "Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial" 17 : 1854-1861, 2010

7 Moo TA, "Selection criteria for postmastectomy radiotherapy in T1-T2 tumors with 1 to 3 positive lymph nodes" 20 : 3169-3174, 2013

8 Donker M, "Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial" 15 : 1303-1310, 2014

9 Killander F, "Radiotherapy and tamoxifen after mastectomy in postmenopausal women--20 year follow-up of the South Sweden Breast Cancer Group randomised trial SSBCG II : I" 43 : 2100-2108, 2007

10 Boersma LJ, "Radiotherapy after primary CHEMotherapy (RAPCHEM): practice variation in a Dutch registration study (BOOG 2010-03)" 145 : 201-208, 2020

11 Jagsi R, "Radiation field design in the ACOSOG Z0011 (Alliance) trial" 32 : 3600-3606, 2014

12 Leonardi MC, "Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy" 163 : 128-135, 2021

13 Mamounas EP, "Predictors of locoregional recurrence after neoadjuvant chemotherapy : results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27" 30 : 3960-3966, 2012

14 Overgaard M, "Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial" 337 : 949-955, 1997

15 Overgaard M, "Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen : Danish Breast Cancer Cooperative Group DBCG 82c randomised trial" 353 : 1641-1648, 1999

16 Zeidan YH, "Postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes : analysis of the breast international group 02-98 trial" 101 : 316-324, 2018

17 Ohri N, "Postmastectomy radiation in breast cancer patients with pathologically positive lymph nodes after neoadjuvant chemotherapy : usage rates and survival trends" 99 : 549-559, 2017

18 Krug D, "Post-mastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer: a pooled retrospective analysis of three prospective randomized trials" 26 : 3892-3901, 2019

19 Almahariq MF, "Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy" 28 : 930-940, 2021

20 Brackstone M, "Management of the axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO guideline" 39 : 3056-3082, 2021

21 Moo TA, "Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection?" 25 : 1488-1494, 2018

22 Poortmans PM, "Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial" 21 : 1602-1610, 2020

23 박혜진 ; 신경환 ; 김진호 ; 안승도 ; 김자영 ; 박원 ; 김용배 ; 김연주 ; 김진희 ; 김규보 ; 박경란 ; 신현수 ; 정배권 ; 이선영 ; 김수지, "Incorporating Risk Factors to Identify the Indication of Post-mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23)" 대한암학회 49 (49): 739-747, 2017

24 Liveringhouse CL, "Genomically guided breast radiation therapy : a review of the current data and future directions" 6 : 100731-, 2021

25 Wang S, "Effectiveness of the AJCC 8th edition staging system for selecting patients with T1–2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986patients from two institutions" 20 : 792-, 2020

26 Early Breast Cancer Trialists' Collaborative Group, "Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality : meta-analysis of individual patient data for 8135 women in 22 randomised trials" 383 : 2127-2135, 2014

27 Weaver DL, "Effect of occult metastases on survival in node-negative breast cancer" 364 : 412-421, 2011

28 Giuliano AE, "Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis : the ACOSOG Z0011(Alliance)randomized clinical trial" 318 : 918-926, 2017

29 Thorsen LBJ, "DBCG-IMN : a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer" 34 : 314-320, 2016

30 Burstein HJ, "Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021" 32 : 1216-1235, 2021

31 Solá M, "Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000" 20 : 120-127, 2013

32 Chang JH, "Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy" 169 : 507-512, 2018

33 de Boer M, "Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases" 102 : 410-425, 2010

34 김규보 ; 박혜진 ; 신경환 ; 김진호 ; 최두호 ; 박원 ; 안승도 ; 김수산 ; 김대용 ; 김태현 ; 김진희 ; 김지영, "Breast Conservation Therapy versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23" 대한암학회 50 (50): 1316-1323, 2018

35 Galimberti V, "Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial" 14 : 297-305, 2013

36 Reznik J, "Analysis of axillary coverage during tangential radiation therapy to the breast" 61 : 163-168, 2005

37 Dodwell D, "Abstract GS4-02: regional lymph node irradiation in early stage breast cancer: an EBCTCG meta-analysis of 13,000 women in 14 trials" American Association for Cancer Research 2019

38 Kalinsky K, "Abstract GS3-00:first results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/-chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer" American Association for Cancer Research 2021

39 Amin MB, "AJCC Cancer Staging Manual" Springer International Publishing 2017

40 Cortina CS, "A national survey of breast surgeons and radiation oncologists on contemporary axillary management in mastectomy patients" 28 : 5568-5579, 2021

41 Paik S, "A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer" 351 : 2817-2826, 2004

42 Mamounas EP, "21-Gene recurrence score and locoregional recurrence in node-positive/er-positive breast cancer treated with chemo-endocrine therapy" 109 : djw259-, 2017